- The report features Eisai Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and
discontinued projects
Reasons To Buy
- Evaluate Eisai Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Eisai Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eisai Co., Ltd.'s pipeline depth and focus of
pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope
Buy a Sample copy of This Report @ http://www.radiantinsights.com/research/eisai-co-ltd-product-pipelinereview-2016/request-sample
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Eisai Co., Ltd. Snapshot 6
Eisai Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Eisai Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Eisai Co., Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 18
Eisai Co., Ltd. - Pipeline Products Glance 20
Eisai Co., Ltd. - Late Stage Pipeline Products 20
Eisai Co., Ltd. - Clinical Stage Pipeline Products 23
Eisai Co., Ltd. - Early Stage Pipeline Products 26
Eisai Co., Ltd. - Drug Profiles 29
donepezil hydrochloride 29
eribulin mesylate 30
lenvatinib mesylate 36
lorcaserin hydrochloride 43
mitiglinide 47
perampanel 49
clevudine 52
mecobalamin 54
avatrombopag 55
fosravuconazole 57
lemborexant 59
BAN-2401 61
denileukin diftitox 63